Skip to content

Myriad Genetics: Molecular Diagnostic

November 10, 2014

Myriad Genetics, Inc. was founded in 1991 and headquartered in Salt Lake City, Utah. Its international corporate headquarters is located in Zurich, Switzerland.  The firm was one of the first genomic companies, driven by the vision of elucidating the role genes play in human disease and using this critical information to improve patient care by developing novel molecular diagnostic products.

Myriad Genetics operates through three segments: Research, Molecular Diagnostics, and Pharmaceutical and Clinical Services. Its molecular diagnostic tests are designed to analyze genes, diagnose diseases, expression levels, and proteins to assess an individual’s risk of developing disease later in life. It also determines a patient’s likelihood of responding to a particular drug. It also assesses a patient’s risk of disease progression and disease recurrence.

The firm offers a variety of molecular diagnostic tests, such as BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; EndoPredict medicine test for breast cancer; and MELARIS predictive medicine test for melanoma among others.

The company also provides biomarker discovery, and pharmaceutical and clinical services to pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trails.

As part of its drive to add to its diagnostic portfolio that is focused on saving lives and improving the quality of life for patients across major diseases Myriad Diagnostics acquired Crescendo Bioscience in 2014. The firm is a global leader in autoimmune diagnostics. Crescendo is based in South San Francisco, California. It pioneered protein-based diagnostics for monitoring disease activity in patients with rheumatoid arthritis and has a pipeline of products under development for a wide range of autoimmune diseases and conditions.

Myriad Genetics has presence in 128 countries.

 

Advertisements
No comments yet

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: